Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- alectinib
- lasmiditan
Interactions between your drugs
alectinib lasmiditan
Applies to: alectinib, lasmiditan
MONITOR: Coadministration of lasmiditan and agents that lower heart rate may increase the risk of bradycardia. In clinical trials, lasmiditan was associated with heart rate decreases of 5 to 10 beats per minute (bpm) while placebo was associated with decreases of 2 to 5 bpm. In a drug interaction study, a single 200 mg dose of lasmiditan led to an additional heart rate decrease of 5 bpm when given with propranolol.
MANAGEMENT: Caution is advised during coadministration of lasmiditan and agents that lower heart rate if the estimated decrease in heart rate may present a clinical risk. Consider monitoring heart rate in patients for whom the estimated decrease in heart rate may not be tolerated.
References (1)
- (2019) "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company
Drug and food interactions
alectinib food
Applies to: alectinib
ADJUST DOSING INTERVAL: Food significantly enhances the oral bioavailability of alectinib and its major active metabolite, M4. According to the manufacturer, a high-fat, high-calorie meal increased the combined systemic exposure (AUC) of alectinib and M4 by 3.1-fold following oral administration of a single 600 mg dose of alectinib.
MANAGEMENT: To ensure maximal oral absorption, alectinib should be administered with food.
References (1)
- (2015) "Product Information. Alecensa (alectinib)." Genentech
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Lumakras
Lumakras is used to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) or colorectal cancer ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer, such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.